search
Back to results

Study to Assess Hypoallergenicity of a New Amino-acid Based Infant Formula in Children With Cow's Milk Allergy (RAF)

Primary Purpose

Cow's Milk Allergy

Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
New Amino Acid formula
Commercially available Amino Acid Formula
Sponsored by
Laboratorios Ordesa
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Cow's Milk Allergy

Eligibility Criteria

undefined - 12 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Children with documented cow's milk allergy, confirmed by one of the following criteria, within six months prior to study start (visit 2):

    • Positive double-blind, placebo-controlled oral food challenge (DBPCFC) with cow's milk OR
    • Positive open or single-blind oral food challenge with cow's milk carried out under the supervision of a specialist in children with clear immediate reactions and a positive test for specific IgE (in serum [sIgE>0,35 KUI/L] or skin prick test [SPT ≥ 3 mm]) OR
    • Reported convincing allergic symptoms following an exposure to milk or a milk-containing food product and detectable serum milk-specific IgE or positive skin prick test
  • Aged ≤12 years of age at screening.
  • Expected consumption of a minimum of 250ml of study formula per day during the open challenge.
  • Written informed consent from one or both parents (depending on the local legislation) or legal representative.

Exclusion Criteria:

  • Children who receive breastfeeding at study enrolment.
  • Had any chronic medical diseases, chromosomal or major congenital anomalies, or major gastrointestinal disease/abnormalities (other the CMPA); had immunodeficiency; antihistamine [excluding eye drops] use in 7 days prior to a food challenge or oral steroid use within 14 days prior to enrolment; unstable asthma; severe uncontrolled eczema;
  • Severe anaphylactic reaction [required ≥ 2 doses of epinephrine] to milk or breast milk within the past 2 years;
  • Existing illness that could interfere with formula acceptance or identification of allergic reactions.
  • Investigator's uncertainty about the willingness or ability of the parents to comply with the protocol requirements.
  • Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.

Sites / Locations

  • Ospedale Pediatrico Bambino Gesù

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

New Amino Acid formula

Control formula

Arm Description

New Amino-Acid based Infant Formula

Commercially available Amino Acid Formula

Outcomes

Primary Outcome Measures

Hypoallergenicity as Assessed by Reaction to Amino-acid Based Infant Formula
To demonstrate that the test formula does not cause immediate and/or delayed allergic reactions to a double blind placebo control food challenge (DBPCFC) and/or a subsequent open food challenge (OFC). Incidence of immediate and/or delayed allergic reactions to the DBPCFC with the study product and/or active comparator and/or during the subsequent OPEN challenge phase of the study.

Secondary Outcome Measures

Cow's Milk Allergy Related Symptoms
Cow's Milk Allergy related Symptoms recorded at visit 1 and visit 4 using the Vandenplas symptom-based score (SBS). The scoring ranges from 0 to 33. Each symptom has a maximal score of 6, except respiratory symptoms where the maximal score is 3. If final score ≥ 12, the symptoms are likely cow's milk related. This could potentially be CMPA. If final score <12, the symptoms are less likely related to cow's milk. Look for other causes.

Full Information

First Posted
February 11, 2015
Last Updated
January 8, 2020
Sponsor
Laboratorios Ordesa
Collaborators
OPBG Clinical & Research Services S.R.L.
search

1. Study Identification

Unique Protocol Identification Number
NCT02414243
Brief Title
Study to Assess Hypoallergenicity of a New Amino-acid Based Infant Formula in Children With Cow's Milk Allergy
Acronym
RAF
Official Title
A Multicenter, Randomized, Controlled, Cross-over Study to Assess Hypoallergenicity of a New Amino-acid Based Infant Formula in Children With Cow's Milk Allergy
Study Type
Interventional

2. Study Status

Record Verification Date
January 2020
Overall Recruitment Status
Completed
Study Start Date
April 2015 (undefined)
Primary Completion Date
December 30, 2016 (Actual)
Study Completion Date
December 30, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Laboratorios Ordesa
Collaborators
OPBG Clinical & Research Services S.R.L.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a prospective, controlled, multi-country study to verifying the hypoallergenicity of the new amino acid-based formula in infants and children aged< 12 years with documented cow's milk protein allergy (CMPA).
Detailed Description
Not Provided

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cow's Milk Allergy

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
41 (Actual)

8. Arms, Groups, and Interventions

Arm Title
New Amino Acid formula
Arm Type
Experimental
Arm Description
New Amino-Acid based Infant Formula
Arm Title
Control formula
Arm Type
Active Comparator
Arm Description
Commercially available Amino Acid Formula
Intervention Type
Other
Intervention Name(s)
New Amino Acid formula
Intervention Description
Ordesa's Amino-Acid based Infant Formula
Intervention Type
Other
Intervention Name(s)
Commercially available Amino Acid Formula
Intervention Description
Commercially available Amino Acid Formula
Primary Outcome Measure Information:
Title
Hypoallergenicity as Assessed by Reaction to Amino-acid Based Infant Formula
Description
To demonstrate that the test formula does not cause immediate and/or delayed allergic reactions to a double blind placebo control food challenge (DBPCFC) and/or a subsequent open food challenge (OFC). Incidence of immediate and/or delayed allergic reactions to the DBPCFC with the study product and/or active comparator and/or during the subsequent OPEN challenge phase of the study.
Time Frame
14 days
Secondary Outcome Measure Information:
Title
Cow's Milk Allergy Related Symptoms
Description
Cow's Milk Allergy related Symptoms recorded at visit 1 and visit 4 using the Vandenplas symptom-based score (SBS). The scoring ranges from 0 to 33. Each symptom has a maximal score of 6, except respiratory symptoms where the maximal score is 3. If final score ≥ 12, the symptoms are likely cow's milk related. This could potentially be CMPA. If final score <12, the symptoms are less likely related to cow's milk. Look for other causes.
Time Frame
14 days

10. Eligibility

Sex
All
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Children with documented cow's milk allergy, confirmed by one of the following criteria, within six months prior to study start (visit 2): Positive double-blind, placebo-controlled oral food challenge (DBPCFC) with cow's milk OR Positive open or single-blind oral food challenge with cow's milk carried out under the supervision of a specialist in children with clear immediate reactions and a positive test for specific IgE (in serum [sIgE>0,35 KUI/L] or skin prick test [SPT ≥ 3 mm]) OR Reported convincing allergic symptoms following an exposure to milk or a milk-containing food product and detectable serum milk-specific IgE or positive skin prick test Aged ≤12 years of age at screening. Expected consumption of a minimum of 250ml of study formula per day during the open challenge. Written informed consent from one or both parents (depending on the local legislation) or legal representative. Exclusion Criteria: Children who receive breastfeeding at study enrolment. Had any chronic medical diseases, chromosomal or major congenital anomalies, or major gastrointestinal disease/abnormalities (other the CMPA); had immunodeficiency; antihistamine [excluding eye drops] use in 7 days prior to a food challenge or oral steroid use within 14 days prior to enrolment; unstable asthma; severe uncontrolled eczema; Severe anaphylactic reaction [required ≥ 2 doses of epinephrine] to milk or breast milk within the past 2 years; Existing illness that could interfere with formula acceptance or identification of allergic reactions. Investigator's uncertainty about the willingness or ability of the parents to comply with the protocol requirements. Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Claudia Banzato, MD
Organizational Affiliation
Azienda Ospedaliera Universitaria Integrata, Verona, Italy
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Maria Pedrosa, MD
Organizational Affiliation
Hospital Universitario La Paz
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Elena Alonso, MD
Organizational Affiliation
Hospital General Universitario Gregorio Marañón, Madrid, Spain
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Montserrat Bosque, MD
Organizational Affiliation
Hospital Universitario Parc Taulí Sabadell, Barcelona, Spain
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Anna Mª Plaza, MD
Organizational Affiliation
Hospital Sant Joan de Déu, Barcelona, Spain
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ospedale Pediatrico Bambino Gesù
City
Rome
Country
Italy

12. IPD Sharing Statement

Citations:
PubMed Identifier
33006765
Citation
Amari S, Shahrook S, Namba F, Ota E, Mori R. Branched-chain amino acid supplementation for improving growth and development in term and preterm neonates. Cochrane Database Syst Rev. 2020 Oct 2;10(10):CD012273. doi: 10.1002/14651858.CD012273.pub2.
Results Reference
derived

Learn more about this trial

Study to Assess Hypoallergenicity of a New Amino-acid Based Infant Formula in Children With Cow's Milk Allergy

We'll reach out to this number within 24 hrs